Welcome to our dedicated page for Greenwich Lifesciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Greenwich LifeSciences, Inc. filings document the reporting, governance, and public-company controls of a clinical-stage biopharmaceutical issuer developing GLSI-100 through the FLAMINGO-01 breast cancer recurrence program. Recent disclosures include a Form 12b-25 notice for a delayed annual report, proxy materials for the annual meeting, and Form 8-K reports on stockholder voting results.
The filing record also covers auditor appointment and change matters, board-election proposals, ratification of the independent registered public accounting firm, and internal-control disclosures referenced in accounting-firm transition materials.